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Cardiopulmonary bypass (CPB), a supporting system to permit open-heart surgery
generates a whole body inflammatory response leading to the so called "postperfusion
syndrome". Although the typical case suffering from hemorrhagic pulmonary edema
is nowadays rarely seen, the employment of CPB still exposes patients to the
increasedcapillary permeability, increasedinterstitial fluid accumulation, andreduced
organ function, resulting in a delay in postoperative recovery. These damaging effects
associated with CPB are resulted largely from the activation of the complement
cascade, the consequent activation ofpolymorphonuclear leukocytes, and the release
of their inflammatory mediators.
Exposure of blood to the artificial material surfaces in the extracorporeal circuits
has been considered to be the main cause of complement activation and the
subsequent leukocyte activation. However, the involvement of material lndependent
factors such as lung reperfusion in the late phase of CPB have recently been
demonstrated to play an important role in enhancing the inflammatory response.
In this thesis, the inflammatory response, especially the activation of leukocytes in
the pulmonary microcirculation after lung reperfusion, was investigated in animal
experiments and in patients undergoing cardiopulmonary bypass.
Chapter I introduces the problems of the inflammatory response induced by CPB
and outlines the purpose of investigations described in the thesis.
Chapter 2 overviews the current understanding of the whole body inflammatory
response induced by CPB and describes the activation and interaction among
different plasmatic systems and blood cells that lead to this inflammatory response.
The first part of this review describes blood activation initiated by the artificial
materials in the.early phase of CPB; and the second pafi of this review emphasizes
the importance of blood activationinducedbymaterial independentfactors particularly
generated after reperfusion of the lungs in the late phase of CPB.
Chapter 3 gives histological evidence of leukocyte sequesEation in the pulmonary
microcirculation and subsequent leukocyte-mediated lung injury in a standard canine
CPB model, showing that these lung histological changes start mainly after lung
reperfusion in the late phase of CPB. Furthermore, the study demonstrates that the
use of a membrane oxygenator instead of a bubble oxygenator in the extracorporeal
circuit reduces considerably the activation of leukocytes and leukocyte-mediated
lung injury during CPB.
Chapter 4 evaluates the infusion of anisodamine on the inhibition of leukocyte
activation and the consequent leukocyte-mediated lung injury during CPB performed
with a bubble oxygenator. Anisodamine is an anticholinergic agent clinically used for
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improvingmicrocirculation.Themechanisms of this agent, thoughnotfully elucidated,
are related to the inhibition of leukocyte activation. When used in canine CPB by a
bolus injection before CPB followed by continuous infusion during CPB (15 mg/kg
in total), this agent significantly reduced pulmonary leukocyte sequestration as well
as oxygen free radical release during CPB. This effective inhibition of leukocytes by
anisodamine was particularly significant after release of the aortic crossclamp in the
late phase of CPB.
Chapter 5 presents the detection of increased membrane expression of leukocyte
CR3 receptors in patients undergoing cardiopulmonary bypass. An increase of CR3
expression on leukocyte occurs immediately after the start of CPB followed by a
second peak ofexpression after release ofthe aortic crossclamp in the late phase of
CPB. Although the early expression of CR3 during CPB might lead to an increased
leukocyte adherence to the foreign material surfaces, the second phase of leukocyte
CR3 expression mediates leukocyte sequestration in the lungs associated with the
release of inflammatory mediators such as elastase which are detrimental to the host
endothelial cells. The understanding of leukocyte CR3 expression during CPB
provides a useful guidance for the possible blockage of these leukocyte adhesive
receptors by pharmacological inhibitors to reduce the leukocyte-mediated
inflammatory response during CPB.
Chapter 6 demonstrates that the use of heparin-coated extracorporeal circuits
reduces the activation of complement and the release of leukocyte inflammatory
mediators such as leukocyte elastase and tumor necrosis factors. This was particularly
manifestafterreperfusionin the latephase of CPB andafterprotamine administration,
both of which are known to cause complement activation through the classical
pathway. The reduction of blood activation achieved by surface heparin coating.
especially the compromised release of leukocyte inflammatory mediators, offers a
beneficial alternative to those patients who are susceptible to the inflammatory
response generated by CPB.
It is thus concluded that next to blood activation by the extracorporeal circuit in the
early phase of CPB, blood activation is strongly enhanced after lung reperfusion in
the late phase of CPB. The effects initiated during the late phase of CPB are largely
induced by the activation of leukocytes and mediated by leukocyte-derived release
products. Reduction of these activation processes as well as the leukocyte-mediated
lung tissue injury could be achieved in animal experiments by the use of a membrane
oxygenator instead of a bubble oxygenator during CPB and by pharmacological
intervention such as anisodamine. In clinical CPB, the activation of complement and
the release of inflammatory mediators manifested after lung reperfusion could be
reduced by surface immobilization ofheparin onthe materials usedin the extracorporeal
circuits. Although CPB is generally safe and the mortality of conventional heart
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surgery is extremely low, a potential risk of postoperative complications resulting
from this systemic inflammatory response still existparticularly in those patients who
experience arelatively long duration of cardiopulmonary bypass and with a decreased
host defense like the elderly and very young patients. For these patients, the current
feasible modifications in reducing the whole body inflammatory response initiated
by CPB is of particular importance.
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